|
1
|
Menderes G, Clark M and Santin AD: Novel
targeted therapies in uterine serous carcinoma, an aggressive
variant of endometrial cancer. Discov Med. 21:293–303.
2016.PubMed/NCBI
|
|
2
|
Hamilton CA, Cheung MK, Osann K, Chen L,
Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS and Chan
JK: Uterine papillary serous and clear cell carcinomas predict for
poorer survival compared to grade 3 endometrioid corpus cancers. Br
J Cancer. 94:642–646. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boruta DM II, Gehrig PA, Fader AN and
Olawaiye AB: Management of women withuterine papillary serous
cancer: A society of gynecologic oncology (SGO) review. Gynecol
Oncol. 115:142–153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goff BA, Kato D, Schmidt RA, Ek M, Ferry
JA, Munts HG, Cain JM, Tamimi HK, Figge DC and Greer BE: Uterine
papillary serous carcinoma: Patterns of metastatic spread. Gynecol
Oncol. 54:264–268. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lecane PS, Karaman MW, Sirisawad M,
Naumovski L, Miller RA, Hacia JG and Magda D: Motexafin gadolinium
and zinc induce oxidative stress responses and apoptosis in B-cell
lymphoma lines. Cancer Res. 65:11676–11688. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Godwin AK, Meister A, O'Dwyer PJ, Huang
CS, Hamilton TC and Anderson ME: High resistance to cisplatin in
human ovarian cancer cell lines is associated with marked increase
of glutathione synthesis. Proc Natl Acad Sci USA. 89:3070–3074.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mulcahy RT, Untawale S and Gipp JJ:
Transcriptional up-regulation of gamma-glutamylcysteine synthetase
gene expression in melphalan-resistant human prostate carcinoma
cells. Mol Pharmacol. 46:909–914. 1994.PubMed/NCBI
|
|
8
|
Trachootham D, Alexandre J and Huang P:
Targeting cancer cells by ROS-mediated mechanisms: A radical
therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seino M, Ohta T, Sugiyama A, Sakaki H,
Sudo T, Tsutsumi S, Shigeta S, Tokunaga H, Toyoshima M, Yaegashi N
and Nagase S: Metabolomic analysis of uterine serous carcinoma with
acquired resistance to paclitaxel. Oncotarget. 9:31985–31998. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lo M, Wang Y and Gout PW: The x(c)-
cystine/glutamate antiporter: A potential target for therapy of
cancer and other diseases. J Cell Physiol. 215:593–602. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aquilano K, Baldelli S and Ciriolo MR:
Glutathione: New roles in redox signaling for an old antioxidant.
Front Pharmacol. 5:1962014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshikawa M, Tsuchihashi K, Ishimoto T,
Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K,
Kawashiri S, et al: xCT inhibition depletes CD44v-expressing tumor
cells that are resistant to EGFR-targeted therapy in head and neck
squamous cell carcinoma. Cancer Res. 73:1855–1866. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu WJ, Zhang Y, Zeng ZL, Li XB, Hu KS, Luo
HY, Yang J, Huang P and Xu RH: β-phenylethyl isothiocyanate
reverses platinum resistance by a GSH-dependent mechanism in cancer
cells with epithelial-mesenchymal transition phenotype. Biochem
Pharmacol. 85:486–496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma MZ, Chen G, Wang P, Lu WH, Zhu CF, Song
M, Yang J, Wen S, Xu RH, Hu Y and Huang P: Xc- inhibitor
sulfasalazine sensitizes colorectal cancer to cisplatin by a
GSH-dependent mechanism. Cancer Lett. 368:88–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zenlea T and Peppercorn MA:
Immunosuppressive therapies for inflammatory bowel disease.
20:3146–3152. 2014.PubMed/NCBI
|
|
16
|
Zhang W, Trachootham D, Liu J, Chen G,
Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W,
et al: Stromal control of cystine metabolism promotes cancer cell
survival in chronic lymphocytic leukaemia. Nat Cell Biol.
14:276–286. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Podolsky DK: Inflammatory bowel disease. N
Engl J Med. 347:417–429. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nielsen OH, Verspaget HW and Elmgreen J:
Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by
sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment
Pharmacol Ther. 2:203–211. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wahl C, Liptay S, Adler G and Schmid RM:
Sulfasalazine: A potent and specific inhibitor of nuclear factor
kappa B. J Clin Invest. 101:1163–1174. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lo M, Ling V, Low C, Wang YZ and Gout PW:
Potential use of the anti-inflammatory drug, sulfasalazine, for
targeted therapy of pancreatic cancer. Curr Oncol. 17:9–16.
2010.PubMed/NCBI
|
|
21
|
Doxsee DW, Gout PW, Kurita T, Lo M,
Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR and Wang YZ:
Sulfasalazine-induced cystine starvation: Potential use for
prostate cancer therapy. Prostate. 67:162–171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nnrang VS, Pauletti GM, Gout PW, Buckley
DJ and Buckley AR: Sulfasalazine-induced reduction of glutathione
levels in breast cancer cells: Enhancement of growth-inhibitory
activity of Doxorubicin. Chemotherapy. 53:210–217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kagami T, Wang Y, Tien A, Watahiki A, Lo
M, Xue H, Gout P and Wang ZY: Sulfasalazine enhances
growth-inhibitory activity of doxorubicin: Potential use in
combination therapy of advanced prostate cancer. Proc 98th Ann
Assoc Cancer Res (Ros Angeles, CA). 2007.
|
|
24
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao JY and Dixon SJ: Mechanisms of
ferroptosis. Cell Mol Life Sci. 73:2195–2209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Santin AD, Bellone S, Gokden M, Palmieri
M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, et
al: Overexpression of HER-2/neu in uterine serous papillary cancer.
Clin Cancer Res. 8:1271–1279. 2002.PubMed/NCBI
|
|
27
|
Sakaki H, Okada M, Kuramoto K, Takeda H,
Watarai H, Suzuki S, Seino S, Seino M, Ohta T, Nagase S, et al:
GSKJ4, a selective Jumonji H3K27 demethylase inhibitor, effectively
targets ovarian cancer stem cells. Anticancer Res. 35:6607–6614.
2015.PubMed/NCBI
|
|
28
|
Orian-Rousseau V: CD44 acts as a signaling
platform controlling tumor progression and metastasis. Front
Immunol. 6:1542015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tanabe KK, Nishi T and Saya H: Novel
variants of CD44 arising from alternative splicing: Changes in the
CD44 alternative splicing pattern of MCF-7 breast carcinoma cells
treated with hyaluronidase. Mol Carcinog. 7:212–220. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ishimoto T, Nagano O, Yae T, Tamada M,
Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al:
CD44 variant regulates redox status in cancer cells by stabilizing
the xCT subunit of system xc(−) and thereby promotes tumor growth.
Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yae T, Tsuchihashi K, Ishimoto T, Motohara
T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H,
et al: Alternative splicing of CD44 mRNA by ESRP1 enhances lung
colonization of metastatic cancer cell. Nat Commun. 3:8832012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oliver FJ, de la Rubia G, Rolli V,
Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of
poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson
from an uncleavable mutant. J Biol Chem. 273:33533–33539. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shem T, Fan Z, Ghoochani A, Rauh M,
Engelhorn T, Minakaki G, Dörfler A, Klucken J, Buchfelder M,
Eyüpoglu IY and Savaskan N: Sulfasalazine impacts on ferroptotic
cell death and alleviates the tumor microenvironment and
glioma-induced brain edema. Oncotarget. 7:36021–36033. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Misaghi S, Korbel GA, Kessler B, Spooner E
and Ploegh HL: z-VAD-fmk inhibits peptide:N-glycanase and may
result in ER stress. Cell Death Differ. 13:163–165. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Enomoto M, Kizawa D, Ohsawa S and Igaki T:
JNK signaling is converted from anti- to pro-tumor pathway by
Ras-mediated switch of Warts activity. Dev Biol. 403:162–171. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Robe PA, Bentires-Alj M, Bonif M, Rogister
B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP,
et al: In vitro and in vivo activity of the nuclear factor-kappaB
inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res.
10:5595–5603. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Müerköster S, Arlt A, Witt M, Gehrz A,
Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR
and Schäfer H: Usage of the NF-kappaB inhibitor sulfasalazine as
sensitizing agent in combined chemotherapy of pancreatic cancer.
Int J Cancer. 104:469–476. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lay JD, Hong CC, Huang JS, Yang YY, Pao
CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ and Chuang SE:
Sulfasalazine suppresses drug resistance and invasiveness of lung
adenocarcinoma cells expressing AXL. Cancer Res. 67:3878–3887.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Okuno S, Sato H, Kuriyama-Matsumura K,
Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T and Bannai
S: Role of cystine transport in intracellular glutathione level and
cisplatin resistance in human ovarian cancer cell lines. Br J
Cancer. 88:951–956. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang Y, Dai Z, Barbacioru C and Sadée W:
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity
and chemoresistance. Cancer Res. 65:7446–7456. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kandil S, Brennan L and McBean GJ:
Glutathione depletion causes a JNK and p38MAPK-mediated increase in
expression of cystathionine-gamma-lyase and upregulation of the
transsulfuration pathway in C6 glioma cells. Neurochem Int.
56:611–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Roh JL, Kim EH, Jang HJ, Park JY and Shin
D: Induction of ferroptotic cell death for overcoming cisplatin
resistance of head and neck cancer. Cancer Lett. 381:96–103. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dolma S, Lessnick SL, Hahn WC and
Stockwell BR: Identification of genotype-selective antitumor agents
using synthetic lethal chemical screening in engineered human tumor
cells. Cancer Cell. 3:285–296. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yagoda N, von Rechenberg M, Zaganjor E,
Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM,
Boniface JJ, et al: RAS-RAF-MEK-dependent oxidative cell death
involving voltage-dependent anion channels. Nature. 447:864–868.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Irani K, Xia Y, Zweier JL, Sollott SJ, Der
CJ, Fearon ER, Sundaresan M, Finkel T and Goldschmidt-Clermont PJ:
Mitogenic signaling mediated by oxidants in Ras-transformed
fibroblasts. Science. 275:1649–1652. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Garama DJ, Harris TJ, White CL, Rossello
FJ, Abdul-Hay M, Gough DJ and Levy DE: A synthetic lethal
interaction between glutathione synthesis and mitochondrial
reactive oxygen species provides a tumor-specific vulnerability
dependent on STAT3. Mol Cell Biol. 35:3646–3656. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Seino M, Okada M, Sakaki H, Takeda H,
Watarai H, Suzuki S, Seino S, Kuramoto K, Ohta T, Nagase S, et al:
Time-staggered inhibition of JNK effectively sensitizes
chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
Oncol Rep. 35:593–601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Okada M, Kuramoto K, Takeda H, Watarai H,
Sakaki H, Seino S, Seino M, Suzuki S and Kitanaka C: The novel JNK
inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo.
Oncotarget. 7:27021–27032. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jiang L, Kon N, Li T, Wang SJ, Su T,
Hibshoosh H, Baer R and Gu W: Ferroptosis as a p53-mediated
activity during tumour suppression. Nature. 520:57–62. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gilmore TD: Introduction to NF-kappaB:
Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Robe PA, Martin DH, Nguyen-Khac MT, Artesi
M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M and Bours
V: Early termination of ISRCTN45828668, a phase 1/2 prospective,
randomized study of sulfasalazine for the treatment of progressing
malignant gliomas in adults. BMC Cancer. 9:3722009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shitara K, Doi T, Nagano O, Imamura CK,
Ozeki T, Ishii Y, Tsuchihashi K, Takahashi S, Nakajima TE, Hironaka
S, et al: Dose-escalation study for the targeting of CD44v+ cancer
stem cells by sulfasalazine in patients with advanced gastric
cancer (EPOC1205). Gastric Cancer. 20:341–349. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shitara K, Doi T, Nagano O, Fukutani M,
Hasegawa H, Nomura S, Sato A, Kuwata T, Asai K, Einaga Y, et al:
Phase 1 study of sulfasalazine and cisplatin for patients with
CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
Gastric Cancer. 20:1004–1009. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sandborn WJ and Feagan BG: Review article:
Mild to moderate Crohn's disease-defining the basis for a new
treatment algorithm. Aliment Pharmacol Ther. 18:263–277. 2003.
View Article : Google Scholar : PubMed/NCBI
|
